Hafrun Fridriksdottir served as the Executive Vice President and Head of Global R&D at Teva from 2017-2021. She also led Global Generic R&D for Allergan, previously Actavis, until the company merged with Teva in 2016. At Teva, Dr. Fridriksdottir was responsible for all global development activities, including innovative medicines, biosimilars and generics. 

Dr. Fridriksdottir holds a PhD in Physical Pharmacy from the University of Iceland. She has been a strong advocate for diversity and equal opportunity in pharma and was recognized in 2021 by the Association of Icelandic Women in Business (FKA) for her work on motivating and supporting women in business.